Federated Hermes’s Cytokinetics CYTK Stock Holding History

Federated Hermes’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45.8M	Sell	538,022 -161,431	-23%	-$11.6M	0.07%	285
2026 Q1	$46.1M	Buy	699,453 +215,785	+45%	+$13.7M	0.08%	278
2025 Q4	$30.7M	Buy	483,668 +457,874	+1,775%	+$28.5M	0.05%	353
2025 Q3	$1.42M	Buy	25,794 +1,405	+6%	+$57.9K	﹤0.01%	1035
2025 Q2	$806K	Sell	24,389 -9,656	-28%	-$336K	﹤0.01%	1207
2025 Q1	$1.37M	Sell	34,045 -3,056	-8%	-$140K	﹤0.01%	1028
2024 Q4	$1.75M	Buy	37,101 +3,546	+11%	+$184K	﹤0.01%	964
2024 Q3	$1.77M	Buy	33,555 +7,457	+29%	+$416K	﹤0.01%	959
2024 Q2	$1.41M	Buy	26,098 +17,530	+205%	+$1.06M	﹤0.01%	1000
2024 Q1	$601K	Buy	+8,568	New	+$663K	﹤0.01%	1287
2023 Q2	–	Sell	-164,500	Closed	-$5.79M	–	2125
2023 Q1	$5.79M	Hold	164,500	–	–	0.01%	659
2022 Q4	$7.54M	Buy	164,500 +164,494	+2,741,567%	+$7.08M	0.02%	604
2022 Q3	$1K	Buy	+6	New	+$289	﹤0.01%	2028
2022 Q1	–	Sell	-245,198	Closed	-$11.2M	–	2220
2021 Q4	$11.2M	Buy	+245,198	New	+$9.46M	0.02%	613
2020 Q4	–	Sell	-348	Closed	-$8K	–	2257
2020 Q3	$8K	Sell	348 -33,403	-99%	-$781K	﹤0.01%	1977
2020 Q2	$796K	Buy	33,751 +31,527	+1,418%	+$591K	﹤0.01%	1328
2020 Q1	$26K	Sell	2,224 -94,540	-98%	-$1.21M	﹤0.01%	1758
2019 Q4	$1.03M	Sell	96,764 -834,163	-90%	-$8.57M	﹤0.01%	1263
2019 Q3	$10.6M	Buy	930,927 +909,472	+4,239%	+$11.4M	0.03%	559
2019 Q2	$241K	Buy	21,455 +20,004	+1,379%	+$193K	﹤0.01%	1532
2019 Q1	$12K	Buy	1,451 +593	+69%	+$4.36K	﹤0.01%	1844
2018 Q4	$5K	Buy	858 +375	+78%	+$2.75K	﹤0.01%	1977
2018 Q3	$5K	Hold	483	–	–	﹤0.01%	2052
2018 Q2	$4K	Hold	483	–	–	﹤0.01%	2038
2018 Q1	$3K	Sell	483 -1,580	-77%	-$13.5K	﹤0.01%	2020
2017 Q4	$17K	Buy	2,063 +1,580	+327%	+$17.9K	﹤0.01%	1794
2017 Q3	$7K	Hold	483	–	–	﹤0.01%	1905
2017 Q2	$6K	Hold	483	–	–	﹤0.01%	1911
2017 Q1	$6K	Hold	483	–	–	﹤0.01%	1899
2016 Q4	$6K	Hold	483	–	–	﹤0.01%	1905
2016 Q3	$4K	Hold	483	–	–	﹤0.01%	1938
2016 Q2	$5K	Hold	483	–	–	﹤0.01%	1892
2016 Q1	$3K	Sell	483 -53,544	-99%	-$391K	﹤0.01%	1931
2015 Q4	$565K	Buy	54,027 +53,173	+6,226%	+$522K	﹤0.01%	1255
2015 Q3	$6K	Buy	+854	New	+$5.83K	﹤0.01%	1764
2014 Q2	–	Sell	-158,400	Closed	-$1.5M	–	1967
2014 Q1	$1.5M	Buy	+158,400	New	+$1.43M	0.01%	1052

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federated Hermes's CYTK Position: Q2 2026 in Review

Federated Hermes reduced its Cytokinetics (CYTK) stake by 23% in Q2 2026, selling an estimated $11.6M and leaving 538,022 shares worth $45.8M. The position accounts for 0.07% of the portfolio, ranked #285.

Federated Hermes first reported a position in CYTK in Q1 2014 and has held it in 36 quarters since. The position peaked at $46.1M in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Federated Hermes held 538,022 shares of Cytokinetics worth $45.8M as of Q2 2026.
Federated Hermes sold 161,431 Cytokinetics shares in Q2 2026, an estimated $11.6M.
Cytokinetics made up 0.07% of Federated Hermes's portfolio in Q2 2026, its #285 holding.
Federated Hermes first reported a position in Cytokinetics in Q1 2014 and has held it in 36 quarters since.
Federated Hermes's Cytokinetics position peaked at $46.1M in Q1 2026.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.